In a similar way, both ccRCC and PRCC exploit the chronic hyperactivation of NRF2 and transcription of antioxidant genes and drug metabolizing enzymes to overcome radio- and chemotherapy-induced cytotoxicity. This evidence concerns the gene NFE2L2 and nonpapillary renal cell carcinoma.